Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis
Pharmakologische Interventionen zur Prävention der Kardiotoxizität bei Patient:innen unter anthrazyklinbasierter Chemotherapie: Netzwerk-Metaanalyse
Frontiers in Cardiovascular Medicine · 03.09.2025 · 12
DOI: 10.3389/fcvm.2025.1612060 ↗Auf einen Blick
28 randomisierte kontrollierte Studien mit 2.858 Patient:innen: Spironolacton und Dexrazoxan zeigten die stärksten Effekte auf LVEF bzw. kardiale Ereignisse.
Fragestellung
Wie wirksam sind pharmakologische Therapien zur Vorbeugung anthrazyklinbedingter Kardiotoxizität?
Methode
Netzwerk-Metaanalyse randomisierter kontrollierter Studien; Suche in EMBASE, Cochrane Library, PubMed, Web of Science und Scopus bis April 2024; nur englischsprachige Arbeiten.
Ergebnisse
28 RCTs mit 2.858 Patient:innen. Spironolacton verbesserte LVEF (MD 12,10; 95 %-KI 7,50–16,70) und LVESD (MD −5,00; 95 %-KI −7,68–−2,32). Dexrazoxan senkte kardiale Ereignisse (OR 0,28; 95 %-KI 0,16–0,50).
Schlussfolgerung der Autor:innen
Spironolacton und Dexrazoxan verhinderten nach den Studienergebnissen den Abfall der LVEF und das Auftreten kardialer Ereignisse signifikant im Vergleich zu Placebo oder konventioneller Chemotherapie.
Kernaussagen
- Spironolacton zeigte die stärkste Verbesserung der LVEF
- Dexrazoxan senkte kardiale Ereignisse am deutlichsten
- Für LVEDD zeigte keine Intervention einen statistisch signifikanten Effekt
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 03.09.2025. Verfasst von Xiaoyu Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
This study evaluates the efficacy of various pharmacological therapies in mitigating the cardiotoxicity associated with anthracycline chemotherapy and furnishes contemporary, evidence-based guidelines and recommendations for clinical practice.
Methods
We searched the EMBASE, Cochrane Library, PubMed, Web of Science, and Scopus databases from the beginning of each database to April 2024 and were limited to English-language documents. The primary objective of this study is to assess the efficacy of cardioprotective drugs in preventing the reduction of left ventricular ejection fraction (LVEF) and the incidence of cardiac events. The secondary objective is to evaluate the impact of these drugs on reducing left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD), as well as on maintaining the ratio of peak mitral annular diastolic velocity to atrial contraction velocity (E/A ratio).
Results
54,852 studies were retrieved from five databases, and 28 randomized controlled trials involving 2,858 patients were finally included. Network Meta-analysis results showed that, compared to the control group, Spironolactone demonstrated the most significant improvement in (LVEF [MD = 12.10, 95% CI (7.50, 16.70)] and LVESD [MD = −5.00, 95% CI (−7.68, −2.32)]. For reducing cardiac events, Dexrazoxane [OR = 0.28, 95% CI (0.16, 0.50)] and Vitamin E combined with Levocarnitine [OR = 0.27, 95% CI (0.08, 0.90)] were the most effective interventions. In terms of diastolic function (E/A ratio), Nebivolol outperformed other β-blockers [MD = 0.23, 95% CI (0.09, 0.37)]. However, no intervention demonstrated a statistically significant effect on LVEDD.
Conclusion
According to the research findings, Spironolactone and Dexrazoxane significantly prevent the decline in LVEF and the occurrence of cardiac events compared to placebo or conventional chemotherapy, with statistical significance. This discovery provides valuable reference for the clinical prevention of anthracycline chemotherapy-induced cardiotoxicity, contributing to the optimization of treatment regimens, reduction of cardiac toxicity risks in patients, and improvement of prognosis. Systematic Review Registration PROSPERO (CRD42024567684).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Nursing, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, China.
Zitieren
APA
Liu, X., Ding, R., & Zhang, A. (2025). Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis. Frontiers in Cardiovascular Medicine, 12. https://doi.org/10.3389/fcvm.2025.1612060
Vancouver
Liu X, Ding R, Zhang A. Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis. Frontiers in Cardiovascular Medicine. 2025;12. doi:10.3389/fcvm.2025.1612060
BibTeX
@article{Liu2025,
author = {Liu, Xiaoyu and Ding, Ran and Zhang, Aihua},
title = {Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis},
journal = {Frontiers in Cardiovascular Medicine},
year = {2025},
volume = {12},
doi = {10.3389/fcvm.2025.1612060}
}
EUVIMED